Full Press Release Details
WARREN, N.J. , April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.
The inducement grant was approved by PTC's Compensation Committee on April 13, 2026, and is being made as an inducement material to the employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $70.42 per share, the closing price of PTC's common stock on April 13, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the employee's new hire date until fully vested, subject to the employee's continued service with the company through the vesting dates.
For more information, please contact: